SARS-CoV-2 | Coronavirus diagnostics by EUROIMMUNContact

The complete package for COVID-19 diagnostics

Our product portfolio for SARS-CoV-2 provides you with the appropriate tools to answer all your diagnostic questions. It comprises three PCR tests for acute diagnostics, serological tests for differentiated detection of antibodies (IgA, IgM, IgG) against different SARS-CoV-2 antigens, a surrogate virus neutralisation test and an interferon-gamma release assay. The detection of specific anti-SARS-CoV-2 IgG using ELISA can be performed using not only venous blood samples, but also dried capillary blood (dried blood spots – DBS).

All tests are CE-marked. Moreover, the Anti-SARS-CoV-2 ELISA (IgG) and the EURORealTime SARS-CoV-2 have been approved for use in authorised laboratories by the U.S. Food and Drug Administration (FDA) via an Emergency Use Authorization (EUA)
Please consider the current US-specific instruction for use of the respective test system for validity of the FDA EUA.


Suitable for acute COVID-19 diagnostics

Direct detection of the virus via RNA (RT-PCR) allow reliable identification of acute SARS-CoV-2 infections. With the EURORealTime SARS-CoV-2, the EURORealTime SARS-CoV-2 Fast and the EURORealTime SARS-CoV-2/Influenza A/B, EUROIMMUN offers two single-parameter tests for detection of the virus as well as a combination test for parallel detection of SARS-CoV-2 and influenza virus types A and B as well as for differentiation between these viruses.

Detection of antibodies and T cell activity

For evaluation of the humoral and cellular immune response to SARS-CoV-2

The portfolio contains several ELISAs, a chemiluminescence immunoassay (ChLIA) and one immunoblot for the detection of antibodies against modified nucleocapsid protein (IgM and IgG) and against the domains S1 and S2 of the spike protein (IgA and IgG). The S1-based test systems Anti-SARS-CoV-2 QuantiVac ELISA (IgG) and Anti-SARS-CoV-2 RBD ChLIA (IgG) allow for quantification of the antibody concentration with the possibility of conversion into standardised units (BAU/ml). In addition, EUROIMMUN offers the Anti-SARS-CoV-2 Omicron ELISA (IgG), which uses the S1 domain of the SARS-CoV-2 Omicron variant. The serological product range is supplemented by the SARS-CoV-2 NeutraLISA, a surrogate virus neutralisation test for the detection of neutralising anti-S1/RBD antibodies, and the interferon-gamma release assay Quan-T-Cell for determination of the activity of SARS-CoV-2-reactive T cells. Both test systems are useful tools for evaluation of the immune response after infection with SARS-CoV-2 or vaccination with vaccines based on the spike protein. With the IgG ELISAs, dried capillary blood (dried blood spots, DBS) can be used as sample material, besides venous blood.


Customer feedback & references

The ELISAs are used worldwide by renowned diagnostic laboratories, reference institutes, clinics and research institutions in order to diagnose and investigate COVID-19.

Customer feedback & publications

Blood collection card

For easy collection of blood samples from the fingertip

The EUROIMMUN Blood collection card can be used for sample collection and mailing of dried capillary blood samples (dried blood spots – DBS). It is suitable either for personal use in a home environment or for blood collection performed by a healthcare professional. The subsequent investigation of the samples for specific IgG antibodies against SARS-CoV-2 is performed in a laboratory.


Information material

Download flyers and further information material here.